ENहिन्दी
Home/Start here/It's for a family member
Reading path3 guides, in order

Someone in my family might need a GLP-1. How do I help?

For anyone helping a parent, partner or relative decide, and then supporting them through it.

GLP Guidebook teamUpdated 5 Oct 20264 min read19 sourcesWritten from published sources
The short answer

Read the basics together, talk without blame, and go to the appointment with them. Weight is driven by genes and surroundings, not just willpower. GLP-1 medicines are usually long-term and cost thousands of rupees a month. Older parents need extra care with fluids, low sugar and muscle.

Read this page first. It covers how to bring it up, who pays, what to watch for in an older parent and whether to go to the appointment. At the end, three guides take you further, in order.
On this page
  1. Talking without shame
  2. Who pays, and for how long
  3. An older parent
  4. Going to the appointment
  5. The risks, in brief
  6. What to read next
  7. Sources

How do I bring it up without shame?

Talk about health and how they feel, not how they look. And drop the blame.

A group of international experts agreed that obesity is not a choice.1 It comes mainly from genes and the world around us.1

Shame also backfires. People who fear being judged are less likely to seek care.1

  • Avoid words like "lazy" or "greedy", even as a joke. The experts' pledge rejects them.1
  • Start from what they care about: energy, knees, sugar levels, keeping up with grandchildren.
  • Ask "How can I help?" rather than telling them what to do.
  • Ask before you share their health with other relatives.

Who pays, and for how long?

Plan for a monthly cost that may run for years, not weeks.

Most of the weight usually returns after stopping. In a follow-up of the main semaglutide 2.4 mg (Wegovy) trial, people regained about two-thirds of it within a year of stopping.2 So agree early who pays, and for how long.

  • Generic semaglutide launched in March 2026. Pens launched at MRPs of about ₹1,800 to ₹4,200 for 4 starting doses, depending on the brand. Natco's vials are priced separately, from ₹1,290 a month.17,18,3,19
  • Ozempic and Wegovy's lowest dose has an MRP of ₹1,415 a week (₹5,660 a month) since a March 2026 price cut.4
  • Mounjaro pens have an MRP of ₹13,125 for 4 starting doses, rising to ₹25,781 at the top dose, as listed by pharmacies.16,12

Higher doses usually cost more, and tests and doctor visits add to it. Prices change often. Guide 6 has the current all-in cost.

What should I watch for in an older parent?

Older adults do take these medicines. Watch three things closely: fluids, low sugar and muscle.

In the main Ozempic trials, 744 people, about 1 in 4 of those taking part, were 65 or older. No overall differences in safety or effect were seen between older and younger people.6

  • Fluids. Vomiting or diarrhoea can dry them out and harm the kidneys.6 Check they're drinking enough, especially in summer.
  • Low sugar. If they take insulin or a sulfonylurea (an older diabetes tablet such as glimepiride), the risk of a hypo (low blood sugar) goes up.6 Learn the signs: dizziness, sweating, shakiness, confusion.6
  • Muscle. Part of the weight lost is lean mass (everything that isn't fat, including muscle), and older age raises the risk of muscle loss (sarcopenia).7 Ask the doctor about protein and safe exercise.
  • Other tablets. These medicines slow the stomach, which can change how other tablets are absorbed.6 Keep a full list of everything they take.

Should I go to the appointment with them?

If they'd like you there, yes. India's obesity guideline says family should be part of clinic visits.8

It says this helps family learn about food and activity, and become a support system.8

Book the right kind of doctor. A government statement of 1 April 2026 said only endocrinologists (hormone and diabetes specialists), internal-medicine specialists and cardiologists (heart specialists) can prescribe GLP-1 medicines.13,9 Minutes of expert committees at CDSCO, India's central drug regulator, attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.14,15

Take with you

  • A list of all their medicines, including ayurvedic or herbal ones
  • Recent reports: HbA1c, kidney tests, blood pressure readings
  • "Which medicine and dose, and why this one?"
  • "Which side effects should we call you about?"
  • "How will we know it's working, and when do we review?"
  • "What will it cost each month, all-in?"
If they have diabetesShould they consider it?Cost calculator

What to read next, in order

These three guides go deeper. Each one ends with a link to the next, so you can read them one after another.

  1. 1Do I have obesity? What Indian BMI and waist numbers meanGuide 1 of 9UnderstandUnderstand their numbers first: Indian BMI and waist cut-offs, and links with diabetes.
  2. 2Should I consider a GLP-1? And when not toGuide 4 of 9DecideWho doctors may consider for a GLP-1, and the reasons not to, including age and kidneys.
  3. 3Side effects and risksGuide 5 of 9DecideKnow the side effects together, so you both know which ones need help fast.
Was this page easy to understand?

Sources

  1. Rubino F et al. Joint international consensus statement for ending stigma of obesity. Nature Medicine, 2020;26:485–497. Statements 6.2 and 10.3, and Box 1. Declared interests: 15 of 36 authors declare ties to Novo Nordisk and 2 to Eli Lilly; Novo Nordisk was one of the sponsors of the meeting's travel costs (paper's own declaration). Full text
  2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–1564. 327 people followed for a year after stopping. DOI
  3. Pearce IP. Generic semaglutide launches in India, including by Dr Reddy's, Zydus, Alkem, Sun Pharma, Glenmark. 21 March 2026. Link
  4. Reuters (via Yahoo Finance). Novo Nordisk cuts prices of Ozempic, Wegovy in India. 31 March 2026. Link
  5. Business Standard. Eli Lilly launches Mounjaro in India. 20 March 2025. Link
  6. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, revised May 2026. Sections 4, 5.3, 5.5, 5.6, 7.2, 8.5. (US label; India's CDSCO label is not published online.) PDF
  7. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 2024;26(Suppl 4):16–27. DOI
  8. Madhu SV, Kapoor N, Das S et al. ESI clinical practice guidelines for the evaluation and management of obesity in India: an update (2025). Indian Journal of Endocrinology and Metabolism, 2025;29(4):355–365. Recommendations B.1 and D.3. DOI
  9. Outlook India. Inspections, surveillance to continue against unauthorised sale, promotion of GLP-1 weight-loss drugs: Govt. 1 April 2026. Link
  10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021;384:989–1002. 1,961 adults without diabetes, 68 weeks. DOI
  11. Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026. Sections 1, 2.2, 5.2, 5.3, 5.5, 8.3, 17. (US label.) PDF
  12. Business Standard (citing Reuters). Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity (one-month supply: 2.5 mg ₹14,000 up to 15 mg ₹27,500). 13 August 2025. These launch MRPs came before the GST on medicines fell from 12% to 5% on 22 September 2025; today's MRPs are in source 16. Link
  13. Press Information Bureau (PIB Research). GLP-1 Drugs: Use, Risks, and Regulation ("In India, GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists"). 1 April 2026. PDF
  14. CDSCO. Subject Expert Committee (Endocrinology & Metabolism), recommendations of 20–21 April 2023, tirzepatide ("The drug should be sold by retail under prescription of Endocrinologist or internal medicine specialists only"). PDF · Archived copy
  15. CDSCO. Subject Expert Committee (Endocrinology & Metabolism), recommendations of 13–14 February 2024, semaglutide (approved warning: "To be sold by retail on the prescription of an Endocrinologist, and Internal medicine"). PDF · Archived copy
  16. Mounjaro KwikPen MRP per pen of 4 doses, as listed by pharmacies that agree (PharmEasy, updated 1 October 2026; MrMed; Tata 1mg): 2.5 mg ₹13,125; 5 mg ₹16,406; 7.5 and 10 mg ₹20,625; 12.5 and 15 mg ₹25,781. These equal Lilly's August 2025 launch MRPs less the GST cut on medicines from 12% to 5% on 22 September 2025 (₹14,000 × 105/112 = ₹13,125). Checked 5 October 2026.
  17. Alkem Laboratories. Press release: semaglutide launch ("pre-filled disposable injection pen, containing four doses for a month, at an affordable price starting INR 1,800"). 21 March 2026. PDF
  18. Dr Reddy's Laboratories. Press release: Obeda (semaglutide) 2 mg and 4 mg pens, "INR 4,200 per month for both the strengths". 21 March 2026. Link
  19. BusinessToday. NATCO opens semaglutide market at ₹1,290 (multi-dose vials, "prices starting at ₹1,290 per month for lower strengths and going up to ₹1,750 for the highest strength"). 20 March 2026. Link

Last checked 5 Oct 2026 · Next review due Jan 2027

How this page was made. Written by the GLP Guidebook team from the sources above: drug labels, published trials, Indian and international guidelines, and named news reports. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write